Clinical Trial Update: Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating patritumab deruxtecan in combination with pembrolizumab and other anticancer agents for high-risk early-stage triple-negative or HR-l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Patritumab Deruxtecan (patritumab deruxtecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Breast Neoplasms, Breast Cancer | Phase 2 | Status: RECRUITING